Phase III results from a clinical trial of a typhoid conjugate vaccine (TCV), EuTYPH-C Inj. Multi-dose, demonstrate that it ...
The addition of neoadjuvant trastuzumab deruxtecan (T-DXd; Enhertu) significantly improved pathologic complete response (pCR) ...
Merck has entered a definitive agreement to acquire Cidara Therapeutics, a biotechnology company developing drug-Fc conjugate ...
Merck and Cidara Therapeutics, Inc., have entered into a definitive agreement under which Merck will acquire Cidara for $9.2 ...
The vaccine effectiveness of PCV20 against IPD and all-cause pneumonia was highest among individuals aged 65 to 74 years and decreased with increasing age.
Mersana Therapeutics' decision earlier this year to go all-in on its antibody-drug conjugate Emi-Le appears to have paid ...
PATH and EuBiologics Co., LTD are pleased to announce Phase 3 results from a clinical trial of a typhoid conjugate vaccine (TCV), EuTYPH-C Inj.® Multi-dose. EuTYPH-C Inj.® ...
Strategic transaction supports the advancement of Decoy’s rapid computational design and manufacturing of innovative peptide conjugate ...
Postmarket surveillance data revealed that enfortumab vedotin (EV) skin toxicity is associated with high hospitalization and ...
Merck & Co. is spending $9.2 billion for Cidara Therapeutics and its lead influenza antiviral that was dropped by Johnson & ...
Trastuzumab emtansine is linked to a lower incidence of decrease in left ventricular ejection fraction than other trastuzumab ...
Merck & Co., Inc. acquires Cidara Therapeutics, Inc. for $9.2bn, boosting its pipeline with CD388's strong flu data. Click ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback